The Lancet Infectious Diseases
ISSN 1473-3099 · Elsevier BV · United Kingdom · active 1897–2026
Metrics
“Cites per paper” is a two-year cited-by rate computed from OpenAlex. It is not a Clarivate Journal Impact Factor — we neither compute nor license that metric. Citation rates differ enormously between fields, so compare within a discipline.
Indexing & access
Access status: unknown. Where this comes from publisher-level signals rather than works-level data it is a heuristic — confirm on the journal’s own site, especially regarding any article processing charge.
Scope
Frequently asked
Is The Lancet Infectious Diseases a predatory journal?
Our screening does not flag The Lancet Infectious Diseases. That is not a guarantee of quality — it means the venue is not on Beall's archive (frozen since 2017) and does not match our name-pattern heuristic. It is listed in Scopus, Web of Science, PubMed, which is a positive signal.
Is The Lancet Infectious Diseases indexed in Scopus or Web of Science?
Per our venue index, The Lancet Infectious Diseases appears in: Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.
What is The Lancet Infectious Diseases's impact?
Papers in The Lancet Infectious Diseases are cited about 9.8 times each within two years of publication, and Scimago places it in Q1, with an h-index of 370. This is not a Clarivate Journal Impact Factor — we neither compute nor license that metric — and a citation rate is a property of a field as much as of a journal.
Is The Lancet Infectious Diseases open access?
We hold no reliable open-access classification for The Lancet Infectious Diseases. Check the journal's own site for its access model and any article processing charge.
Similar venues
- MMWR Morbidity and Mortality Weekly ReportQ1 · Centers for Disease Control and Prevention
- Clinical Microbiology ReviewsQ1 · American Society for Microbiology
- Biotechnology AdvancesQ1 · Elsevier BV
- EurosurveillanceQ1 · European Centre for Disease Prevention and Control
- Current Opinion in Chemical EngineeringQ1 · Elsevier BV
- Current Opinion in BiotechnologyQ1 · Elsevier BV